Roger Jeffs, Liquidia CEO
June 29, 2023 04:01 PM EDT
R&D

Liq­uidia and Unit­ed Ther­a­peu­tics could bring new lung in­di­ca­tion in­to le­gal saga

Katherine Lewin

News Reporter

Liq­uidia said in an SEC fil­ing Wednes­day that it will “ag­gres­sive­ly de­fend” against a po­ten­tial new patent cov­er­ing Unit­ed Ther­a­peu­tics’ tre­pros­tinil …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times